Fust Matthew K 4

What Happened

• Matthew K. Fust, a director of Neumora Therapeutics, was granted a derivative equity award covering 80,000 shares on May 27, 2026. The Form 4 lists the transaction as an award/grant (code A) with a reported price of $0.00. This was a grant of an option/derivative interest (not a sale); no cash was paid in connection with the grant as reported.

Key Details

• Transaction date: 2026-05-27; filing date: 2026-05-29 (filed timely within required Form 4 window).
• Transaction type: Award/Grant of a derivative (code A) covering 80,000 shares; price reported $0.00.
• Shares owned after transaction: not specified in the information provided on this summary (check the full Form 4 for total beneficial ownership).
• Footnote: F1 — 100% of the shares subject to the option vest on the earlier of (i) the one-year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
• No 10b5-1 plan, tax-withholding, or sale reported in this filing.

Context

• This filing reflects a grant of a derivative award (an option-like instrument) rather than an open-market purchase or sale. The award vests based on time/meeting condition per the footnote; it does not indicate an immediate exercise or sale of shares. For investors, grants show insider compensation and potential future dilution but are not direct cash purchases indicating personal bullishness.